Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Immune Checkpoint Inhibitor and Expand Immune-Oncology Portfolio

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immune-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce that it has entered into an asset purchase agreement dated November 28, 2024 (the “Agreement”), with Laevoroc Immunology AG (“Laevoroc Immunology”), a privately-held, Swiss immune-oncology company.

Read the full press release here.

Newswire | EIN Newswire

One Reply on “Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Immune Checkpoint Inhibitor and Expand Immune-Oncology Portfolio”

Comments are closed.